How PIK3CG Becomes a Key Target for Melatonin Intervention in Sepsis-Induced Myocardial Injury

1. Concept

Sepsis, a systemic inflammatory response triggered by infection, frequently leads to multiple organ dysfunction—with the heart being one of the most severely affected organs. Sepsis patients with myocardial injury face a mortality rate of 70%-90%, significantly higher than those without cardiac involvement. Despite advancements in intensive care and anti-infection therapies, sepsis-related mortality remains on the rise, highlighting an urgent need for effective therapeutic strategies. The pathological mechanisms of sepsis-induced myocardial injury are complex, involving excessive inflammatory activation, oxidative stress imbalance, and mitochondrial dysfunction. Traditional single-target therapies struggle to address this multi-factorial, multi-pathway process. Melatonin, a neuroendocrine hormone with antioxidant and anti-inflammatory properties, has emerged as a potential protective agent. Through network pharmacology and experimental validation, PIK3CG (the γ catalytic subunit of phosphatidylinositol 3-kinase) has been identified as a key target mediating melatonin’s cardioprotective effects, offering a new direction for targeted therapy.

2. Research Frontiers

2.1 Clinical Challenges of Sepsis-Induced Myocardial Injury

Sepsis-induced myocardial injury poses significant clinical hurdles:

• High mortality rates (70%-90%) due to the interconnected nature of inflammatory responses, oxidative stress, and mitochondrial dysfunction.
• Limitations of traditional therapies: Single-target approaches fail to address the multi-pathway pathological cascade, leading to suboptimal clinical outcomes.
• Unmet need for multi-target interventions: Identifying key regulatory nodes that integrate multiple pathological processes is critical for developing effective treatments.

2.2 The Application Value of PIK3CG Recombinant Rabbit Monoclonal Antibodies

The PIK3CG recombinant rabbit monoclonal antibody is a critical tool for studying sepsis-induced myocardial injury, with core applications including:

• Expression and activity detection: Western blot analysis quantifies PIK3CG expression and phosphorylation levels in myocardial tissues of sepsis models, enabling assessment of pathway activation.
• Subcellular localization: Immunofluorescence techniques reveal PIK3CG distribution in cardiomyocytes, clarifying its role in intracellular signal transduction.
• Protein-protein interaction studies: Co-immunoprecipitation experiments using the antibody identify PIK3CG’s downstream signaling partners, mapping the regulatory network.
• Drug mechanism validation: Evaluates melatonin’s effects on the PIK3CG pathway, providing experimental evidence for target-mediated therapy.

2.3 Network Pharmacology Identifies PIK3CG as a Key Target

A multi-strategy integrated analysis led to the identification of PIK3CG:

• Data integration: Sepsis-related gene sets from database mining, differentially expressed genes (778 totalsup) from RNA sequencing, and weighted gene co-expression network analysis (WGCNA) were combined to screen core regulatory modules.
• Hub gene identification: A protein-protein interaction network was constructed, highlighting 66 hub genes. PIK3CG exhibited high topological importance, indicating a central regulatory role.
• Molecular docking: Simulations confirmed melatonin can form stable interactions with PIK3CG, computationally validating it as a potential target.

2.4 Melatonin’s Protective Role in Sepsis-Induced Myocardial Injury

Melatonin exerts cardioprotective effects through multiple mechanisms:

• Antioxidant activity: Scavenges reactive oxygen species (ROS), induces antioxidant enzyme expression, and maintains mitochondrial homeostasis.
• Anti-inflammatory effects: Modulates the NLRP3 inflammasome and Mst1/JNK pathways, reducing pro-inflammatory cytokine secretion (IL-6, TNF-α).
• Multi-pathway regulation: Targets PIK3CG to integrate inflammatory and oxidative stress signaling, addressing the complex pathology of sepsis-induced myocardial injury.

2.5 Experimental Validation of PIK3CG’s Key Role

In vitro and in vivo experiments confirm PIK3CG’s necessity for melatonin’s protective effects:

• Cell models: PIK3CG knockdown weakened melatonin’s ability to inhibit inflammation and oxidative stress, while overexpression enhanced its cardioprotective effects.
• Animal models: Modulating PIK3CG activity altered myocardial inflammatory response intensity, oxidative stress levels, and apoptosis rates, aligning with network pharmacology predictions. These results validate PIK3CG as a central regulatory node in sepsis-induced myocardial injury.

2.6 Clinical Implications and Future Directions

This research holds significant clinical value and points to future directions:

• Mechanistic insights: Provides a molecular basis for melatonin’s clinical application in sepsis-induced myocardial injury.
• Therapeutic target development: PIK3CG emerges as a novel target for developing targeted drugs to treat sepsis-related cardiac dysfunction.
• Future research focus: Elucidating PIK3CG’s downstream signaling mechanisms, conducting large-scale clinical trials to validate melatonin’s efficacy, and exploring combination therapies with PIK3CG-targeted agents.

3. Research Significance

Identifying PIK3CG as a key target for melatonin intervention has profound scientific and clinical significance:

• Scientific value: Integrates network pharmacology and experimental validation to uncover a novel regulatory pathway, advancing understanding of sepsis-induced myocardial injury’s complex mechanisms.
• Clinical value: Validates melatonin as a potential therapeutic agent and PIK3CG as a target, offering a multi-pathway intervention strategy to improve outcomes for sepsis patients with myocardial injury.

4. Related Mechanisms, Research Methods, and Product Applications

4.1 Core Mechanism of Melatonin-PIK3CG-Mediated Cardioprotection

Melatonin protects against sepsis-induced myocardial injury through the PIK3CG pathway:

1. Sepsis activates inflammatory signaling (TNF-α, IL-6, NLRP3 inflammasome) and oxidative stress (ROS, NOX2), leading to cardiomyocyte damage and apoptosis.
2. Melatonin binds to PIK3CG (p110γ), activating the PI3K/Akt signaling pathway.
3. Activated Akt inhibits pro-inflammatory cytokine production, reduces ROS generation, and suppresses caspase-1-mediated cell death, preserving myocardial function.

4.2 Key Research Methods

The study integrates diverse research approaches to validate PIK3CG as a target:

• Network pharmacology: Database mining, RNA sequencing, WGCNA, and molecular docking to predict key targets.
• In vitro experiments: Cell models (cardiomyocytes) to assess PIK3CG knockdown/overexpression effects on melatonin’s protective function.
• In vivo experiments: Sepsis mouse models to evaluate melatonin’s effects on myocardial injury, PIK3CG pathway activation, inflammation, and oxidative stress.
• Biochemical assays: Western blot, immunofluorescence, co-immunoprecipitation, and ELISA to detect protein expression, localization, and cytokine levels.

4.3 Product Applications: ANT BIO PTE. LTD.’s PIK3CG Recombinant Rabbit Monoclonal Antibody

ANT BIO PTE. LTD.’s STARTER brand offers the “PIK3CG Recombinant Rabbit mAb (Catalog No.: S0B1448)”—a high-performance tool for PI3K pathway research.

Core Product Advantages

• High specificity and isoform selectivity: Specifically recognizes PIK3CG (p110γ) with minimal cross-reactivity to other PI3K isoforms (p110α, β, δ), ensuring low background and clear signals.
• Multi-platform validation: Validated for Western blot (WB), immunoprecipitation (IP), and immunofluorescence (IF), supporting diverse experimental needs.
• Stability and batch consistency: Strict quality control ensures reliable, reproducible results across experiments, facilitating long-term research.

Key Application Scenarios

• Cardiovascular research: Studying PIK3CG’s role in sepsis-induced myocardial injury, myocardial contraction, and angiogenesis.
• Inflammation and immunology: Exploring PIK3CG-mediated immune cell activation (neutrophils, macrophages) and inflammatory response regulation.
• Tumor research: Analyzing PIK3CG’s function in tumor-associated macrophages (TAMs) and the immunosuppressive microenvironment.
• Drug development: Validating PIK3CG as a target for anti-inflammatory, antioxidant, or cardioprotective drugs.

ANT BIO PTE. LTD. provides comprehensive technical support, including activation state detection protocols, co-localization study guidelines, and expert consultation for experimental design.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with high-quality, innovative research tools and solutions. As a leader in life science reagents, we offer a comprehensive portfolio under three sub-brands: Absin (focused on general reagents and kits), Starter (specialized in antibodies), and UA (dedicated to recombinant proteins).

Our commitment to excellence is underpinned by advanced development platforms—including recombinant rabbit/mouse monoclonal antibody platforms, rapid monoclonal antibody development, recombinant protein expression systems (E. coli, CHO, HEK293, Insect Cells), One-Step ELISA Platforms, and PTM Pan-Modification Antibody Platforms—alongside rigorous quality control systems. We hold international certifications such as EU 98/79/EC, ISO9001, and ISO13485, ensuring our products meet the highest global standards.

Our mission is to accelerate scientific discovery, facilitate translational research, and contribute to the development of novel therapies for human health. By partnering with researchers in academia and biopharmaceutical companies worldwide, we strive to be a trusted collaborator in advancing life science research and addressing unmet medical needs.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.